{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:20:54Z","timestamp":1787912454032,"version":"build-2784847793"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.coi.2025.102632","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T19:01:44Z","timestamp":1754938904000},"page":"102632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Can juvenile idiopathic arthritis be cured?"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9164-1632","authenticated-orcid":false,"given":"Shwetha","family":"Maharaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102632_bib1","article-title":"Advancements and progress in juvenile idiopathic arthritis: a review of pathophysiology and treatment","volume":"103","author":"Huang","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.coi.2025.102632_bib2","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.coi.2025.102632_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-021-00629-8","article-title":"Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches","volume":"19","author":"Zaripova","year":"2021","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.coi.2025.102632_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cells9102301","article-title":"The multi-omics architecture of juvenile idiopathic arthritis","volume":"9","author":"Hou","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.coi.2025.102632_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4049\/jimmunol.1800636","article-title":"LACC1 regulates TNF and IL-17 in mouse models of arthritis and inflammation","volume":"202","author":"Skon-Hegg","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102632_bib6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2016-04-712612","article-title":"CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency","volume":"128","author":"Lo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102632_bib7","first-page":"157","article-title":"Rheumatoid arthritis: inheritance and association with other autoimmune diseases","volume":"4","author":"Grennan","year":"1986","journal-title":"Dis Markers"},{"key":"10.1016\/j.coi.2025.102632_bib8","first-page":"496","article-title":"Genetic factors in thyroid disease","volume":"4","author":"Muzza","year":"2018","journal-title":"Encycl Endocr Dis"},{"key":"10.1016\/j.coi.2025.102632_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-044452763-9\/50035-4","article-title":"Topoisomerase-I (SCL-70) autoantibodies","author":"Randone","year":"2007","journal-title":"Autoantibodies"},{"key":"10.1016\/j.coi.2025.102632_bib10","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/hep.1840160616","article-title":"Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype","volume":"16","author":"Underhill","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102632_bib11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/rheumatology\/keh489","article-title":"HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women","volume":"44","author":"Loubi\u00e8re","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102632_bib12","unstructured":"Parameswaran P, Lucke M: HLA-B27 Syndromes.\u00a02025."},{"key":"10.1016\/j.coi.2025.102632_bib13","first-page":"1","article-title":"HLA-DRB1 allelic epitopes that associate with autoimmune disease risk or protection activate reciprocal macrophage polarization","volume":"11","author":"van Drongelen","year":"2021","journal-title":"Sci Rep 2021 111"},{"key":"10.1016\/j.coi.2025.102632_bib14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/acr.24853","article-title":"American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coi.2025.102632_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073594","article-title":"Candidates for intra-articular administration therapeutics and therapies of osteoarthritis","volume":"22","author":"Toyoda","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2025.102632_bib16","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/gt.2008.109","article-title":"Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis","volume":"15","author":"Trittibach","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.coi.2025.102632_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-1-61779-095-9_8","article-title":"Lentiviral vectors","volume":"737","author":"Giry-Laterri\u00e8re","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.coi.2025.102632_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13122090","article-title":"mRNA, a revolution in biomedicine","volume":"13","author":"Baptista","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.coi.2025.102632_sbref18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1482728","article-title":"Autoimmune disease: a view of epigenetics and therapeutic targeting","volume":"15","author":"Mu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102632_bib20","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/art.40877","article-title":"Amelioration of autoimmune arthritis in mice treated with the DNA methyltransferase inhibitor 5\u2032-azacytidine","volume":"71","author":"T\u00f3th","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102632_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.leukres.2016.02.005","article-title":"Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"43","author":"Fraison","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.coi.2025.102632_sbref21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41576-023-00662-1","article-title":"Non-coding RNAs in disease: from mechanisms to therapeutics","volume":"25","author":"Nemeth","year":"2023","journal-title":"Nature Reviews Genetics"},{"key":"10.1016\/j.coi.2025.102632_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197015","article-title":"Treg enhancing therapies to treat autoimmune diseases","volume":"21","author":"Eggenhuizen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2025.102632_sbref23","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2025.102632_sbref24","article-title":"AB0816 treatment of a patient with severe diffuse systemic sclerosis (SSC) using CD19-targeting CAR-T-cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102632_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/antib13010010","article-title":"Immunotherapy strategy for systemic autoimmune diseases: betting on CAR-T cells and antibodies","volume":"13","author":"Chasov","year":"2024","journal-title":"Antibodies"},{"key":"10.1016\/j.coi.2025.102632_bib27","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/1756-185X.13527","article-title":"Adult outcome of juvenile idiopathic arthritis: a nationwide population-based retrospective cohort study in Taiwan","volume":"22","author":"Yong","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.coi.2025.102632_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1001\/jamanetworkopen.2024.51341","article-title":"Genetic association of juvenile idiopathic arthritis with adult rheumatic disease","volume":"7","author":"Fan","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:24:03Z","timestamp":1757337843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":28,"alternative-id":["S0952791525001086"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102632","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can juvenile idiopathic arthritis be cured?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102632"}}